{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["crizotinib","pembrolizumab"]],"indication":"untreated ALK-positive advanced non-small cell lung cancer","name":"KEYNOTE 050","nct_id":"NCT02511184","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=keynote-050-nct02511184. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Find and expand the maximum tolerated dose of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks.","label":"Dose finding and dose expansion phases","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2017-12","type":"ACTUAL"},"conditions":["ALK-positive Advanced NSCLC"],"enrollment":{"count":9,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Crizotinib","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"}],"last_update":"2019-07-01","lead_sponsor":"Pfizer","official_title":"A PHASE 1B STUDY OF CRIZOTINIB IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PATIENTS WITH UNTREATED ADVANCED ALK-TRANSLOCATED NON SMALL CELL LUNG CANCER","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2017-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants With Dose-limiting Toxicity (DLT)","timeFrame":"6 weeks"}],"references":[],"start_date":{"date":"2015-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients","url":"https://clinicaltrials.gov/study/NCT02511184"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/keynote-050-nct02511184"}